Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter Phase II Study of 5-Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Newly Diagnosed or Recurrent Malignant Gliomas

NCT01445691 is registered in ClinicalTrials.gov with Constantinos Hadjipanayis as lead sponsor.

NCT NCT01445691
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01445691 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter Phase II Study of 5-Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Newly Diagnosed or Recurrent Malignant Gliomas
Lead sponsor
Constantinos Hadjipanayis
Phase
Phase 2
Overall status
Withdrawn
Start date
November 30, 2015
Completion date
September 30, 2016
Enrollment
0 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

benign neoplasms, brain, brain cancer, brain neoplasms, benign, brain neoplasms, malignant, brain tumor, primary, brain tumor, recurrent, brain tumors, glioblastoma, gliomas, intracranial neoplasms, neoplasms, brain, neoplasms, intracranial, primary brain neoplasms, primary malignant brain neoplasms, primary malignant brain tumors